SOURCE: Cannabis & Tech Today
In a long-awaited announcement, the Drug Enforcement Agency (DEA) agreed to reschedule cannabis from a Schedule I to a Schedule III narcotic. Additional steps, including a public comment period and White House approval, must be completed to finalize the reclassification. But for all intents and purposes, a significant milestone appears to have been reached.
The news sent shockwaves through a market and community often riddled with down times in recent years. Across the industry, legal, and advocacy circles, most considered the news a positive step forward, citing expected benefits to medical research and business operations. However, many voiced concerns over the reclassification’s impact on equity, social justice, and market prosperity.
Cannabis & Tech Today compiled quotes from across the industry regarding the rescheduling of cannabis, with excerpts below.
